Qualis Health

Qualis Health is a national leader in improving care delivery and patient outcomes, working with clients throughout the public and private sector to advance the quality, efficiency, and value of healthcare for millions of Americans every day. We deliver solutions to ensure that our partners transform the care they provide, with a focus on process improvement, care management, and effective use of health information technology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

CHIMERON BIO EXPANDS FOOTPRINT IN PHILADELPHIA BY JOINING BIOLABS AT THE CURTIS

Chimeron Bio | January 25, 2022

news image

Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and internationally. The move stems from Chimeron’s need for an expanded footprint to accommodate its growing R&D team and operations....

Read More

MEDICAL

PHAGENOVA BIO, INC. ANNOUNCES PUBLICATION DESCRIBING NEW METHOD FOR SAFE AND EFFECTIVE PULMONARY DELIVERY OF THERAPEUTICS

PhageNova Bio, Inc. | December 14, 2020

news image

PhageNova Bio, Inc. ("PhageNova") is pleased to declare the distribution of information created through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press distribution) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, portrays another technique for protected and effective pulmonary delivery of therapeutics, including an aerosol vaccination strategy which is being developed to address...

Read More

INDUSTRIAL IMPACT

LINKINVAX AND INSERM TRANSFERT ENTER INTO AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT COVERING USE OF AN INNOVATIVE VACCINE PLATFORM

LinKinVax technology | February 04, 2022

news image

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action. LinKinVax is developing a vaccine platform that directly targets dendritic cells.These cells play a crucial role in the immune system, stimulating and regulating immune responses. The agreement with Inserm Transfert covers industrial and commercial use, and the...

Read More

CELL AND GENE THERAPY

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

news image

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More
news image

INDUSTRIAL IMPACT

CHIMERON BIO EXPANDS FOOTPRINT IN PHILADELPHIA BY JOINING BIOLABS AT THE CURTIS

Chimeron Bio | January 25, 2022

Chimeron Bio, a biotechnology company pioneering a novel class of self-amplifying RNA-vaccines and therapeutics announced its plan to expand operations in the Philadelphia area and move to The Curtis, a landmark site in Center City Philadelphia under BioLabs, the leading developer and operator of life science co-working spaces in the U.S. and internationally. The move stems from Chimeron’s need for an expanded footprint to accommodate its growing R&D team and operations....

Read More
news image

MEDICAL

PHAGENOVA BIO, INC. ANNOUNCES PUBLICATION DESCRIBING NEW METHOD FOR SAFE AND EFFECTIVE PULMONARY DELIVERY OF THERAPEUTICS

PhageNova Bio, Inc. | December 14, 2020

PhageNova Bio, Inc. ("PhageNova") is pleased to declare the distribution of information created through a sponsored research agreement with Rutgers, The State University of New Jersey. The Med (a Cell Press distribution) article, entitled Targeted Phage Display-Based Pulmonary Vaccination in Mice and Non-human Primates, portrays another technique for protected and effective pulmonary delivery of therapeutics, including an aerosol vaccination strategy which is being developed to address...

Read More
news image

INDUSTRIAL IMPACT

LINKINVAX AND INSERM TRANSFERT ENTER INTO AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT COVERING USE OF AN INNOVATIVE VACCINE PLATFORM

LinKinVax technology | February 04, 2022

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action. LinKinVax is developing a vaccine platform that directly targets dendritic cells.These cells play a crucial role in the immune system, stimulating and regulating immune responses. The agreement with Inserm Transfert covers industrial and commercial use, and the...

Read More
news image

CELL AND GENE THERAPY

EXUMA BIOTECH COMPLETES SERIES B2 TO ADVANCE NOVEL CELL & GENE THERAPIES

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and con...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us